For US Healthcare Professionals

Updated Guidance: VYJUVEK is now approved for use from birth, can be applied by a caregiver or patient at-home, has an increased weekly volume, & has the flexibility of being removed at your next dressing change.

For the treatment of dystrophic epidermolysis bullosa (DEB)1

Activate Powerful DEB Wound Healing With VYJUVEK1

VYJUVEK is the FIRST and ONLY treatment that addresses
the genetic cause of DEB to provide powerful wound healing
in a topical gel1

See the Results
Campaign image
Droplet icon

How VYJUVEK Works

Learn more about the mechanism of action

Mechanism of Action
DNA icon

VYJUVEK Efficacy & Safety

See the results of the GEM-3 trial

VYJUVEK Results
Download file icon

How to Start Patients on VYJUVEK

View resources for your practice and your patients

Getting Started
INDICATION AND USAGE

VYJUVEK is a topical gel indicated for the treatment of wounds in adult and pediatric patients (from birth) with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Accidental Exposure to VYJUVEK gel: VYJUVEK will not replicate in the subject’s cells and does not integrate into the subject cells’ native genetic material. For precautions, avoid direct contact with treated wounds (e.g., touching or scratching) and dressings of treated wounds until the next dressing change following treatment. Wear protective gloves when assisting patients with changing wound dressings and handling the disposal. In the event of accidental exposure (e.g., through a splash to the eyes or mucous membranes), flush with clean water for at least 15 minutes.

Clean all surfaces that may have come in contact with VYJUVEK biological suspension or gel and treat all spills with a virucidal agent.

Dispose all materials (e.g., vial, syringe, cleaning materials) that may have come in contact with VYJUVEK biological suspension or gel into a biohazard container.

ADVERSE REACTIONS

The most common adverse reactions (>5%) were itching, chills, redness, rash, cough, and runny nose.


  • Please see Important Safety Information above and click here for full Prescribing Information.
Reference

1. VYJUVEK [prescribing information]. Krystal Biotech, Inc.; 2025.

IMPORTANT SAFETY INFORMATION
INDICATION AND USAGE

VYJUVEK is a topical gel indicated for the treatment of wounds in adult and pediatric patients (from birth) with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Accidental Exposure to VYJUVEK gel: VYJUVEK will not replicate in the subject’s cells and does not integrate into the subject cells’ native genetic material. For precautions, avoid direct contact with treated wounds (e.g., touching or scratching) and dressings of treated wounds until the next dressing change following treatment. Wear protective gloves when assisting patients with changing wound dressings and handling the disposal. In the event of accidental exposure (e.g., through a splash to the eyes or mucous membranes), flush with clean water for at least 15 minutes.

Clean all surfaces that may have come in contact with VYJUVEK biological suspension or gel and treat all spills with a virucidal agent.

Dispose all materials (e.g., vial, syringe, cleaning materials) that may have come in contact with VYJUVEK biological suspension or gel into a biohazard container.

ADVERSE REACTIONS

The most common adverse reactions (>5%) were itching, chills, redness, rash, cough, and runny nose.


  • Please see Important Safety Information above and click here for full Prescribing Information.
Reference

1. VYJUVEK [prescribing information]. Krystal Biotech, Inc.; 2025.